Verzistobart Biosimilar – Anti-T-cell immunoglobulin mucin receptor 3 mAb – Research Grade from ProteoGenix; catalogue PX-TA1977; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Verzistobart Biosimilar is a novel therapeutic antibody that targets the T-cell immunoglobulin mucin receptor 3 (TIM-3). This biosimilar is a research grade antibody that has shown promising results in pre-clinical studies for the treatment of various diseases. In this article, we will provide a scientific description of the structure, activity, and potential applications of Verzistobart Biosimilar.
Verzistobart Biosimilar is a monoclonal antibody (mAb) that specifically targets the TIM-3 receptor. It is a humanized antibody, meaning that it is derived from a non-human source, but has been modified to be more similar to human antibodies. The antibody is composed of two identical heavy chains and two identical light chains, each with a variable region and a constant region.
The variable region of the antibody is responsible for binding to the TIM-3 receptor. It is highly specific and recognizes a specific epitope on the receptor. The constant region, on the other hand, is responsible for the effector functions of the antibody, such as activating the immune system to fight against the targeted cells.
Verzistobart Biosimilar works by binding to the TIM-3 receptor on the surface of T-cells. TIM-3 is a protein that is expressed on the surface of various immune cells, including T-cells, and plays a crucial role in regulating immune responses. When Verzistobart Biosimilar binds to TIM-3, it blocks the interaction between TIM-3 and its ligands, which are molecules that activate the receptor.
This blockade of TIM-3 signaling has been shown to have multiple effects on the immune system. It can enhance the function of T-cells, leading to increased anti-tumor activity. It can also modulate the activity of other immune cells, such as dendritic cells and natural killer cells, to improve the overall immune response against diseases.
Verzistobart Biosimilar has shown promising results in pre-clinical studies for the treatment of various diseases. Its ability to modulate the immune response makes it a potential therapeutic option for a wide range of conditions. Some of the potential applications of Verzistobart Biosimilar are discussed below.
The overexpression of TIM-3 has been observed in various types of cancer, including lung, breast, and colon cancer. Verzistobart Biosimilar has shown promising results in pre-clinical studies for the treatment of these cancers. By blocking TIM-3 signaling, it can enhance the anti-tumor activity of T-cells and improve the overall immune response against cancer cells.
TIM-3 has been implicated in the development of autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. Verzistobart Biosimilar has shown potential in pre-clinical studies for the treatment of these diseases by modulating the immune response and reducing inflammation.
infectious diseases, such as HIV and hepatitis B. Verzistobart Biosimilar has shown potential in pre-clinical studies for the treatment of these diseases by enhancing the immune response and reducing the viral load.
In summary, Verzistobart Biosimilar is a research grade antibody that targets the TIM-3 receptor. It has a specific structure and activity that allows it to modulate the immune response and potentially treat various diseases, including cancer, autoimmune diseases, and infectious diseases. Further clinical studies are needed to fully understand the potential applications of this novel therapeutic antibody.
ProteoGenix catalogue number PX-TA1977. For research use only.
Target: Verzistobart Biosimilar – Anti-T-cell immunoglobulin mucin receptor 3 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: 0.01M PBS, pH 7.4; Applications: WB, ELISA, Flow Cyt.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Verzistobart Biosimilar – Anti-T-cell immunoglobulin mucin receptor 3 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
